Karyopharm Therapeutics Inc (KPTI) Receives Average Recommendation of “Buy” from Brokerages

Shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) have earned an average recommendation of “Buy” from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $18.50.

A number of analysts recently commented on KPTI shares. BidaskClub raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, February 9th. Cantor Fitzgerald reissued a “buy” rating and issued a $18.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, January 25th. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, December 12th. Royal Bank of Canada reissued a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd.

Karyopharm Therapeutics (KPTI) traded up $0.21 on Wednesday, hitting $14.98. The company had a trading volume of 377,900 shares, compared to its average volume of 253,752. The firm has a market capitalization of $706.77, a price-to-earnings ratio of -5.63 and a beta of 4.11. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $15.61.

In other news, SVP Christopher Brett Primiano sold 27,042 shares of the firm’s stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $10.28, for a total value of $277,991.76. Following the transaction, the senior vice president now directly owns 11,381 shares in the company, valued at approximately $116,996.68. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Sharon Shacham sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $12.50, for a total value of $125,000.00. Following the completion of the transaction, the insider now owns 723,510 shares in the company, valued at $9,043,875. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 78,542 shares of company stock worth $819,692. Company insiders own 14.71% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC raised its holdings in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after purchasing an additional 4,444 shares during the period. Wells Fargo & Company MN raised its holdings in shares of Karyopharm Therapeutics by 18.8% in the 4th quarter. Wells Fargo & Company MN now owns 30,974 shares of the company’s stock worth $298,000 after purchasing an additional 4,902 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after purchasing an additional 5,586 shares during the period. California State Teachers Retirement System raised its holdings in shares of Karyopharm Therapeutics by 12.2% in the 2nd quarter. California State Teachers Retirement System now owns 59,844 shares of the company’s stock worth $542,000 after purchasing an additional 6,500 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in shares of Karyopharm Therapeutics by 33.6% in the 2nd quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock worth $255,000 after purchasing an additional 7,099 shares during the period. Institutional investors own 56.56% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://stocknewstimes.com/2018/02/19/karyopharm-therapeutics-inc-kpti-receives-average-recommendation-of-buy-from-brokerages.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply